The 5-year survival rate for moderately differentiated carcinoma of the juxta-abdomen is about 60% or more. Moderately differentiated carcinoma of the jugular region is a common type of adenocarcinoma and is also a moderately differentiated type of cancer. The cure rate of moderately differentiated carcinoma of the jugular abdomen depends on its different locations and the stage of the cancer, and the cure rate varies depending on the degree of response to treatment. If patients with early stage of moderately differentiated carcinoma of the jugular abdomen can be detected, diagnosed and treated early, the cure rate of early stage moderately differentiated carcinoma may be more than 98%. If patients with intermediate stage moderately differentiated carcinoma of the juxta-juxta-abdomen can be treated actively, through surgery, with chemotherapy (such as mitomycin, cytarabine, vincristine, etc.), radiotherapy, and targeted drug therapy. Most of the patients are able to prolong their lives, with a five-year survival rate of about 60%. Patients with advanced moderately differentiated carcinoma of the jugular abdomen can extend their life by 1-3 years with active treatment. It is recommended that patients with moderately differentiated carcinoma of the jugular abdominal region should be actively treated as soon as possible to avoid delaying their condition.